JP2001507687A - ピロロ〔3,4−d〕ピリミジノン誘導体および医薬としてのその使用 - Google Patents

ピロロ〔3,4−d〕ピリミジノン誘導体および医薬としてのその使用

Info

Publication number
JP2001507687A
JP2001507687A JP52869798A JP52869798A JP2001507687A JP 2001507687 A JP2001507687 A JP 2001507687A JP 52869798 A JP52869798 A JP 52869798A JP 52869798 A JP52869798 A JP 52869798A JP 2001507687 A JP2001507687 A JP 2001507687A
Authority
JP
Japan
Prior art keywords
methyl
pyrrolo
naphthalenylmethyl
formula
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP52869798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001507687A5 (cg-RX-API-DMAC10.html
Inventor
クーパー,マーティン
チェシア,デイヴィッド
ドナルド,デイヴィッド
ファーバー,マーク
ペリー,マシュー
ハリスン,リチャード
トムキンスン,ニコラス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2001507687A publication Critical patent/JP2001507687A/ja
Publication of JP2001507687A5 publication Critical patent/JP2001507687A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP52869798A 1996-12-21 1997-12-18 ピロロ〔3,4−d〕ピリミジノン誘導体および医薬としてのその使用 Ceased JP2001507687A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9626643.2A GB9626643D0 (en) 1996-12-21 1996-12-21 Compounds
GB9626643.2 1996-12-21
PCT/SE1997/002157 WO1998028301A1 (en) 1996-12-21 1997-12-18 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments

Publications (2)

Publication Number Publication Date
JP2001507687A true JP2001507687A (ja) 2001-06-12
JP2001507687A5 JP2001507687A5 (cg-RX-API-DMAC10.html) 2005-08-11

Family

ID=10804862

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52869798A Ceased JP2001507687A (ja) 1996-12-21 1997-12-18 ピロロ〔3,4−d〕ピリミジノン誘導体および医薬としてのその使用

Country Status (23)

Country Link
US (8) US6046204A (cg-RX-API-DMAC10.html)
EP (1) EP0946562B1 (cg-RX-API-DMAC10.html)
JP (1) JP2001507687A (cg-RX-API-DMAC10.html)
KR (1) KR20000069605A (cg-RX-API-DMAC10.html)
CN (1) CN1246119A (cg-RX-API-DMAC10.html)
AT (1) ATE215088T1 (cg-RX-API-DMAC10.html)
AU (1) AU717429B2 (cg-RX-API-DMAC10.html)
BR (1) BR9714063A (cg-RX-API-DMAC10.html)
CA (1) CA2275312A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ289925B6 (cg-RX-API-DMAC10.html)
DE (1) DE69711430T2 (cg-RX-API-DMAC10.html)
EE (1) EE9900315A (cg-RX-API-DMAC10.html)
GB (1) GB9626643D0 (cg-RX-API-DMAC10.html)
HU (1) HUP0002839A3 (cg-RX-API-DMAC10.html)
ID (1) ID21682A (cg-RX-API-DMAC10.html)
IL (1) IL130538A0 (cg-RX-API-DMAC10.html)
IS (1) IS5082A (cg-RX-API-DMAC10.html)
NO (1) NO993027L (cg-RX-API-DMAC10.html)
NZ (1) NZ336124A (cg-RX-API-DMAC10.html)
PL (1) PL334228A1 (cg-RX-API-DMAC10.html)
SK (1) SK76699A3 (cg-RX-API-DMAC10.html)
TR (1) TR199901433T2 (cg-RX-API-DMAC10.html)
WO (1) WO1998028301A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091223A1 (en) * 2002-04-23 2003-11-06 Sankyo Company, Limited Pyrimidine derivative

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
AU2107700A (en) 1999-01-15 2000-08-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridine-n-oxides with pde-iv inhibiting activity
EP1147103B1 (en) 1999-01-15 2005-05-04 ALTANA Pharma AG Phenantrhridine-n-oxides with pde-iv inhibiting activity
ATE356810T1 (de) 1999-01-15 2007-04-15 Altana Pharma Ag Polysubstituted 6-phenylphenanthridines mit pde- iv hemmender wirkung
US6361486B1 (en) * 2000-02-29 2002-03-26 Agilent Technologies, Inc. Coaxial-drive centrifuge providing tilt control relative to centrifugal force
US20070105841A1 (en) * 2000-08-14 2007-05-10 Breitenbucher J G Method for treating allergies using substituted pyrazoles
US7589202B2 (en) * 2000-08-14 2009-09-15 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
CA2533534C (en) * 2003-07-24 2013-03-19 Tecomet, Inc. Assembled non-random foams
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
DK2024367T3 (da) 2006-05-04 2011-01-03 Pulmagen Therapeutics Inflammation Ltd Tetrahydropyrrolopyrimidindioner og deres anvendelse som inhibitorer af human neutrofil elastase
US8198288B2 (en) 2006-05-04 2012-06-12 Pulmagen Therapeutics (Inflammation) Limited Tetrahydropyrrolopyrimidinediones and their use in therapy
AU2007256633B2 (en) 2006-06-06 2013-09-12 Intra-Cellular Therapies, Inc. Organic compounds
ES2588238T3 (es) 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
WO2009100403A1 (en) * 2008-02-07 2009-08-13 Neurogen Corporation Substituted aryl pyrimidinones
MX2011005934A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
BRPI0922700A2 (pt) 2008-12-06 2015-08-11 Intracellular Therapies Inc Compostos orgânicos
AU2009322899A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
EP2464354B1 (en) 2009-08-10 2015-04-01 The Regents of The University of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
EP2575817A4 (en) 2010-05-31 2014-01-08 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
USRE48842E1 (en) 2011-05-27 2021-12-07 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
CN108129486B (zh) * 2018-01-25 2020-06-05 华东理工大学 嘧啶酮衍生物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004047A1 (en) * 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
GB9424842D0 (en) * 1994-12-09 1995-02-08 British Tech Group Pharmaceutical compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091223A1 (en) * 2002-04-23 2003-11-06 Sankyo Company, Limited Pyrimidine derivative

Also Published As

Publication number Publication date
PL334228A1 (en) 2000-02-14
US6136974A (en) 2000-10-24
AU717429B2 (en) 2000-03-23
US6211368B1 (en) 2001-04-03
CN1246119A (zh) 2000-03-01
GB9626643D0 (en) 1997-02-12
CA2275312A1 (en) 1998-07-02
AU5580998A (en) 1998-07-17
US6306863B1 (en) 2001-10-23
EP0946562A1 (en) 1999-10-06
US6046204A (en) 2000-04-04
ATE215088T1 (de) 2002-04-15
BR9714063A (pt) 2002-01-02
TR199901433T2 (xx) 1999-09-21
CZ289925B6 (cs) 2002-04-17
NZ336124A (en) 2001-03-30
ID21682A (id) 1999-07-08
NO993027D0 (no) 1999-06-18
IL130538A0 (en) 2000-06-01
KR20000069605A (ko) 2000-11-25
EP0946562B1 (en) 2002-03-27
US6166206A (en) 2000-12-26
SK76699A3 (en) 2000-05-16
DE69711430T2 (de) 2002-10-31
US20030162798A1 (en) 2003-08-28
US20020025966A1 (en) 2002-02-28
EE9900315A (et) 2000-02-15
IS5082A (is) 1999-06-14
DE69711430D1 (de) 2002-05-02
HUP0002839A2 (hu) 2001-02-28
CZ220499A3 (cs) 2000-02-16
WO1998028301A1 (en) 1998-07-02
HUP0002839A3 (en) 2001-04-28
NO993027L (no) 1999-08-20
US6229013B1 (en) 2001-05-08

Similar Documents

Publication Publication Date Title
US6306863B1 (en) Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments
JP2001520645A (ja) 新規な化合物
JP2002500666A (ja) 新規な化合物
US8372854B2 (en) Pyrrolo[2,3-D]pyrimidine compounds
JP2002523511A (ja) 新規化合物
JP2022526827A (ja) (e)-3-[2-(2-チエニル)ビニル]-1h-ピラゾールの固体形態
RU2699034C1 (ru) Способ получения соединений 7H-пирроло[2,3-d]пиримидина
US20050065168A1 (en) Process for purifying N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide(zaleplon) and crystalline forms of zaleplon accessible with the process
US20050245750A1 (en) Process for preparing 1,3-benzodioxole-2-spirocycloalkane derivative
US20060270690A1 (en) N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto
US5281708A (en) 9-Substituted-8-halo or -8-hydroxy-9-deazaguanines as inhibitors of PNP
JPH0971534A (ja) 医薬組成物
JP2002507987A (ja) 化合物
MXPA99005779A (en) Pyrrolo[3,4-d
CA2357687C (en) New pyridazine endothelin antagonists
WO2025133948A1 (en) Acetyl coa-carboxylase (acc) inhibitors
WO2004004703A1 (ja) メタフェニレンジアミン誘導体
JP3244325B2 (ja) ピリミジン環縮合シクロペンチリデン誘導体
JP2003500356A (ja) シス−[4−シアノ−4−(3−シクロペンチルオキシ−4−メトキシフェニル)シクロヘキサン−1−カルボン酸]の塩
US20050032818A1 (en) N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl]-N-ethylacetamide and crystalline forms of zaleplon
US20070238739A1 (en) Process for purifying N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethylacetamide (zaleplon) and crystalline forms of zaleplon accessible with the process
JP2003512377A (ja) p38プロテインキナーゼのインヒビターとしてのアルキルアミノ置換二環式窒素複素環
JPH07233151A (ja) インダン誘導体、その製法及びその合成中間体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051213

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20060501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060606